What Taro Pharmaceutical Industries does

Taro Pharmaceutical Industries Ltd. is an Israel-headquartered multinational pharmaceutical company founded in 1950 as a collaboration between Israeli pharmacists and American physicians. The company develops, manufactures, and markets a broad portfolio of prescription (Rx) medications, over-the-counter (OTC) products, and cosmetics across therapeutic areas including pain and inflammation, dermatology, cardiovascular, neurology and psychiatry, oncology, ophthalmology, gastroenterology, and endocrinology. Taro's core technical asset is vertical integration: its Chemistry Division in Haifa Bay synthesizes active pharmaceutical ingredients (APIs) across seven production lines, while its Pharma Division manufactures finished dosage forms through dedicated cells for dry-mix, granulation, liquids and foams, and semi-solids. R&D centers in Haifa, Brampton (Canada), and Hawthorne, NY focus on formulation, analytical development, and synthetic organic chemistry, supporting bioequivalence and clinical endpoint studies from pre-clinical through Phase IV.

The company sells its products through four wholly-owned regional subsidiaries — Taro USA, Taro Canada, Taro Israel, and Taro International — distributing Rx, OTC, and cosmetic products through pharmaceutical supply chains across North America, Central America, East Asia, Europe, Australia, and Israel. The revenue model is product sales across three categories (Rx, OTC, cosmetics) plus API manufacturing, with horizontal segmentation across therapeutic areas and persona-level targeting of healthcare professionals and end patients. Pricing is not publicly disclosed. Taro's competitive positioning rests on cGMP compliance certified by the FDA, UK MHRA, and Israeli Ministry of Health; IP-protected branded dermatological products; and leadership in US generic dermatology by 2016. The company was acquired by Sun Pharmaceuticals in 2010, completed an NYSE IPO in 2012 (the same year it surpassed $1B in gross sales), acquired Alchemee in 2022 to expand branded dermatology, and became a private wholly-owned subsidiary of Sun Pharma on June 24, 2024.

Name

Taro Pharmaceutical Industries

Legal name

Taro Pharmaceutical Industries Ltd.

Website

https://taro.co.il

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

101–250 employees

Short description

Taro Pharmaceutical Industries is an Israel-based multinational generic and specialty pharmaceutical manufacturer developing, producing, and distributing Rx, OTC, and cosmetic products across multiple therapeutic areas through regional subsidiaries, now operating as a wholly-owned subsidiary of Sun Pharma since June 2024.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Topical dermatology
• Active pharmaceutical ingredients
• Finished dosage forms

Headquarters

HQ city

Haifa

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Prescription (Rx) Pharmaceutical Products: Revenue from prescription-only medications developed and manufactured by Taro, covering therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, and more.
2. Over-the-Counter (OTC) Products: Revenue from non-prescription products available directly to consumers, including topical formulations and other treatments.
3. Cosmetic Products: Revenue from topical cosmetic products including creams, ointments, lotions, gels, and foams.
4. Active Pharmaceutical Ingredients (API): Manufacturing and sale of active pharmaceutical ingredients used in medications for skin, cardiovascular, pain, and central nervous system conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Taro Pharmaceutical Industries develops, manufactures, and markets a broad portfolio of prescription (Rx), over-the-counter (OTC), and cosmetic pharmaceutical products across therapeutic areas including pain, dermatology, digestive system, nervous system, cardiology, oncology, and ophthalmology. The company is vertically integrated, synthesizing its own active pharmaceutical ingredients (APIs) and producing finished dosage forms in tablets, capsules, creams, ointments, gels, foams, solutions, and injectables. Taro operates R&D centers in Israel, Canada, and the United States, and is recognized as the leading generic dermatological company in the US market.

Product overview

Taro Pharmaceutical Industries is a multinational pharmaceutical company that develops, manufactures, and markets a broad portfolio of prescription (Rx) medications across multiple therapeutic areas including pain/inflammation, dermatology, cardiovascular, neurology/psychiatry, oncology, ophthalmology, and gastroenterology. The company offers products in various delivery forms including tablets, capsules, films, solutions, suspensions, creams, ointments, gels, foams, and injectables. Taro operates through two main divisions: the Pharma Division (manufacturing finished dosage forms including dry-mix, granulation, liquids/foams, and semi-solids production cells) and the Chemistry Division (manufacturing active pharmaceutical ingredients). R&D centers in Haifa (Israel), Brampton (Canada), and Hawthorne (NY, USA) focus on generic and branded products spanning oral solid-dose immediate and modified-release formulations, liquids, and dermatological topical formulations including creams, ointments, lotions, gels, and foams. The company is a leader in topical generic products and has developed extensive over-the-counter (OTC) offerings alongside its Rx portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Aquimod
• Brexin
• Capecitabine Taro
• Cinacalcet Taro
• Coumadin
• Curatane
• Dermacombin
• Diprofol
• Dorzolamide Timolol Taro
• Dutasteride Taro
• Entumin
• Estelle 35
• Etopan
• Etopan XL
• Etoricoxib Taro
• Lataro
• Lataro-Tim
• Lozapine
• Mercaptizol
• Meroken
• Nystatin Ready Mix
• Odomzo
• Otomycin
• Oxacatin
• Paracetamol Taro IV
• Partane
• Percocet
• Perphenan
• Pregabalin Taro
• Profex
• Promnix
• Rokacet Plus
• Sevelamer Taro
• Sterocort
• Taroclindin
• Teril
• Uramox
• Zindaclin 1% Gel
• Zoledronic Acid Taro
• Active Pharmaceutical Ingredients (API)
• Over-the-Counter (OTC) Pharmaceutical Products
• Cosmetic Products

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• Sun Pharmaceutical USAminorOthersAffiliate company of Sun Pharma serving the US market.
• Sun Pharmaceutical EuropeminorOthersAffiliate company of Sun Pharma serving the European market.
• Chattem Chemicals Inc.minorOthersAffiliate company under the Sun Pharma umbrella.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Glenmark Pharmaceuticals: India-based global generic and specialty pharmaceutical company with a notable dermatology franchise. Comparable to Taro on integrated API-to-dosage manufacturing and dermatology emphasis.
• Perrigo Company: US-based generic and OTC pharmaceutical manufacturer with strong consumer self-care and dermatology franchises. Comparable to Taro on the OTC + Rx + dermatology + multi-region distribution model.
• Sandoz: Global generic pharmaceuticals business spun off from Novartis, offering broad Rx generics including dermatology, anti-infectives, and oncology. Comparable to Taro as a vertically capable generic manufacturer serving regulated markets.
• Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer with broad therapeutic coverage including dermatology. Comparable to Taro as a vertically integrated generic player supplying regulated markets.
• Mayne Pharma: Specialty pharmaceutical company with significant generic dermatology and women's health franchises. Comparable to Taro on US-focused generic dermatology leadership and topical formulation capabilities.
• Teva Pharmaceutical Industries: Israel-headquartered global generic pharmaceutical leader with a meaningful dermatology franchise. Taro is most directly comparable to Teva as both are Israeli generic pharma companies with multi-therapeutic portfolios and US market exposure.
• Almirall: European dermatology-focused specialty pharmaceutical company. Directly comparable to Taro on the dermatology specialty positioning, with overlapping therapeutic focus on skin conditions.
• Viatris: Global generics and specialty pharmaceutical company formed from Mylan/Upjohn merger. Comparable to Taro on multi-therapeutic generic portfolio, established dermatology position, and global supply chain scale.
• Lupin Pharmaceuticals: Indian generic pharmaceutical major with US-focused operations across multiple therapeutic areas. Comparable to Taro on US generic commercialization, multi-therapeutic portfolio, and API integration.

Emerging players

• Galderma: Dermatology-focused pharmaceutical and skincare company with strong prescription and consumer brands. Comparable to Taro on the dermatology focus, though more skewed toward branded aesthetics and skin care.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/taro-pharmaceutical-industries

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taro Pharmaceutical Industries